SGLT2 Inhibitors vs GLP-1 Receptor Agonists for Kidney Outcomes in Individuals With Type 2 Diabetes

Do kidney outcomes differ between initiating treatment with a sodium-glucose cotransporter-2 inhibitor (SGLT2i) vs glucagon-like peptide-1 receptor agonist (GLP-1RA) in individuals with type 2 diabetes?In this comparative effectiveness study with a target trial emulation including 36 279 SGLT2i initiators and 18 782 GLP-1RA initiators, SGLT2i initiation was associated with a lower 5-year risk of chronic kidney disease and a lower 5-year count of acute kidney injury compared with GLP-1RA initiation. Findings were consistent across subgroups and most pronounced among individuals without preexisting kidney disease.These findings suggest that initiating treatment with an SGLT2i, compared with a GLP-1RA, is associated with improved kidney outcomes in individuals with type 2 diabetes.

Corresponding Author: Simon K. Jensen, PhD, Aarhus Universitetshospital, Olof Palmes Allé 43-45, 8200 Aarhus N, Denmark (skj@clin.au.dk).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.